Related Experiment Video
Updated: Dec 19, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Advances in Small-Cell Lung Cancer (SCLC) Translational Research
Benjamin J Drapkin1, Charles M Rudin2
1University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Abstract:
Over the past several years, we have witnessed a resurgence of interest in the biology and therapeutic vulnerabilities of small-cell lung cancer (SCLC). This has been driven in part through the development of a more extensive array of representative models of disease, including a diverse variety of genetically engineered mouse models and human tumor xenografts. Herein, we review recent progress in SCLC model development, and consider some of the particularly active avenues of translational research in SCLC, including interrogation of intratumoral heterogeneity, insights into the cell of origin and oncogenic drivers, mechanisms of chemoresistance, and new therapeutic opportunities including biomarker-directed targeted therapies and immunotherapies. Whereas SCLC remains a highly lethal disease, these new avenues of translational research, bringing together mechanism-based preclinical and clinical research, offer new hope for patients with SCLC.
Insights
Recent advances in small-cell lung cancer (SCLC) models have spurred translational research. New therapeutic strategies offer hope for this lethal disease.
Area of Science:
- Oncology
- Cancer Biology
- Translational Research
Background:
- Small-cell lung cancer (SCLC) shows renewed research interest.
- Development of advanced SCLC models, including genetically engineered mouse models and human tumor xenografts, is crucial.
- Understanding SCLC biology and therapeutic vulnerabilities is key.
Purpose of the Study:
- To review progress in SCLC model development.
- To discuss active translational research areas in SCLC.
- To highlight new therapeutic opportunities for SCLC patients.
Main Methods:
- Review of recent advancements in SCLC model systems.
- Analysis of ongoing translational research in SCLC.
- Examination of emerging therapeutic strategies.
Main Results:
- Progress in developing diverse and representative SCLC models.
- Active research into intratumoral heterogeneity, cell of origin, and oncogenic drivers.
- Investigation into chemoresistance mechanisms and novel therapies.
Conclusions:
- Despite its lethality, SCLC research is advancing.
- Mechanism-based preclinical and clinical research offers new hope.
- Biomarker-directed therapies and immunotherapies show promise for SCLC treatment.
